OBJECTIVES: The changes in the serum levels of lipopolysaccharide binding protein (LBP) and sCD14 during cardiac surgery were followed in this study. DESIGN: Thirty-four patients, 17 in each group, were randomly assigned to coronary artery bypass grafting surgery performed either with ("on-pump") or without ("off-pump") cardiopulmonary bypass. LBP and sCD14 were evaluated by ELISA. RESULTS: The serum levels of LBP were gradually increased from the 1st postoperative day and reached their maximum on the 3rd postoperative day in both "on-pump" and "off-pump" patients (30.33+/-9.96 microg/mL; 37.99+/-16.58 microg/mL), respectively. There were no significant differences between "on-pump" and "off-pump" patients regarding LBP. The significantly increased levels of sCD14 from the 1st up to the 7th postoperative day in both "on-pump" and "off-pump" patients were found with no significant differences between these groups. No correlations between LBP and sCD14 and IL-6, CRP and long pentraxin PTX3 levels were found. CONCLUSIONS: The levels of LBP and sCD14 are elevated in cardiac surgical patients being similar in both groups. These molecules are not produced as acute phase proteins in these patients.

Institute of Clinical Immunology and Allergology Charles University Prague School of Medicine and University Hospital in Hradec Králové 500 05 Hradec Kralove Czech Republic

See more in PubMed

Brasil LA, Gomes WJ, Salomão R, Buffolo E. Inflammatory response after myocardial revascularization with or without cardiopulmonary bypass. The Annals of Thoracic Surgery. 1998;66(1):56–59. PubMed

Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. The Annals of Thoracic Surgery. 2003;75(2):S715–S720. PubMed

Chew MS, Brandslund I, Brix-Christensen V, et al. Tissue injury and the inflammatory response to pediatric cardiac surgery with cardiopulmonary bypass: a descriptive study. Anesthesiology. 2001;94(5):745–753. PubMed

Ubenauf KM, Krueger M, Henneke P, Berner R. Lipopolysaccharide binding protein is a potential marker for invasive bacterial infections in children. Pediatric Infectious Disease Journal. 2007;26(2):159–162. PubMed

Hargreaves DC, Medzhitov R. Innate sensors of microbial infection. Journal of Clinical Immunology. 2005;25(6):503–510. PubMed

Kunes P, Lonsky V, Mandak J, et al. The long pentraxin 3 in cardiac surgery: distinct responses in “on-pump” and “off-pump” patients. Scandinavian Cardiovascular Journal. 2007;41(3):171–179. PubMed

Weiss J. Bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP): structure, function and regulation in host defence against Gram-negative bacteria. Biochemical Society Transactions. 2003;31(4):785–790. PubMed

Zweigner J, Schumann RR, Weber JR. The role of lipopolysaccharide-binding protein in modulating the innate immune response. Microbes and Infection. 2006;8(3):946–952. PubMed

Fransen E, Maessen J, Dentener M, Senden N, Buurman W. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest. 1999;116(5):1233–1239. PubMed

Dentener MA, Vreugdenhil ACE, Hoet PHM, et al. Production of the acute-phase protein lipopolysaccharide-binding protein by respiratory type II epithelial cells: implications for local defense to bacterial endotoxins. American Journal of Respiratory Cell and Molecular Biology. 2000;23(2):146–153. PubMed

Zweigner J, Gramm H-J, Singer OC, Wegscheider K, Schumann RR. High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood. 2001;98(13):3800–3808. PubMed

Vreugdenhil ACE, Rousseau CH, Hartung T, Greve JWM, van 't Veer C, Buurman WA. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. The Journal of Immunology. 2003;170(3):1399–1405. PubMed

Pavcnik-Arnol M, Hojker S, Derganc M. Lipopolysaccharide-binding protein in critically ill neonates and children with suspected infection: comparison with procalcitonin, interleukin-6, and C-reactive protein. Intensive Care Medicine. 2004;30(7):1454–1460. PubMed

Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C. CD14 is an acute-phase protein. The Journal of Immunology. 2004;172(7):4470–4479. PubMed

Finberg RW, Re F, Popova L, Golenbock DT, Kurt-Jones EA. Cell activation by Toll-like receptors: role of LBP and CD14. Journal of Endotoxin Research. 2004;10(6):413–418. PubMed

Schmitz G, Orsó E. CD14 signalling in lipid rafts: new ligands and co-receptors. Current Opinion in Lipidology. 2002;13(5):513–521. PubMed

Hiki N, Berger D, Mimura Y, et al. Release of endotoxin-binding proteins during major elective surgery: role of soluble CD14 in phagocytic activation. World Journal of Surgery. 2000;24(5):499–506. PubMed

Takeshita S, Nakatani K, Tsujimoto H, Kawamura Y, Kawase H, Sekine I. Increased levels of circulating soluble CD14 in Kawasaki disease. Clinical & Experimental Immunology. 2000;119(2):376–381. PubMed PMC

Kruger C, Schutt C, Obertacke U, et al. Serum CD14 levels in polytraumatized & severely burned patients. Clinical & Experimental Immunology. 1991;85(2):297–301. PubMed PMC

Arias MA, Rey Nores JE, Vita N, et al. Cutting edge: human B cell function is regulated by interaction with soluble CD14: opposite effects on IgG1 and IgE production. The Journal of Immunology. 2000;164(7):3480–3485. PubMed